Impact of polymorphisms in drug pathway genes on disease-free survival in adults with acute myeloid leukemia

[1]  Ryoichi Takayanagi,et al.  Genetic impact on uric acid concentration and hyperuricemia in the Japanese population. , 2013, Journal of atherosclerosis and thrombosis.

[2]  A. Ashworth,et al.  Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress , 2013, British Journal of Cancer.

[3]  Eurie L. Hong,et al.  Annotation of functional variation in personal genomes using RegulomeDB , 2012, Genome research.

[4]  J. Karp,et al.  The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. , 2012, Pharmacogenomics.

[5]  C. Flowers,et al.  Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Raymond K. Auerbach,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[7]  R. Fanin,et al.  Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin , 2012, The Pharmacogenomics Journal.

[8]  J. Cortes,et al.  Molecular targeted therapy in acute myeloid leukemia , 2012, Hematology.

[9]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[10]  Krishna R. Kalari,et al.  Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer , 2012, Pharmacogenetics and genomics.

[11]  F. Lo‐Coco,et al.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. , 2012, Blood.

[12]  H. Deeg,et al.  Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients , 2011, Journal of clinical pharmacology.

[13]  J. Downing,et al.  Genetic Variants in Cytosolic 5′-Nucleotidase II Are Associated with Its Expression and Cytarabine Sensitivity in HapMap Cell Lines and in Patients with Acute Myeloid Leukemia , 2011, Journal of Pharmacology and Experimental Therapeutics.

[14]  S. Yun,et al.  Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  N. Novitzky,et al.  Is there a role for autologous stem cell transplantation for patients with acute myelogenous leukemia? A retrospective analysis. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Luigi Ferrucci,et al.  Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain , 2010, PLoS genetics.

[18]  J. Beijnen,et al.  P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide , 2009, Clinical Cancer Research.

[19]  Krishna R. Kalari,et al.  Gemcitabine and Arabinosylcytosin Pharmacogenomics: Genome-Wide Association and Drug Response Biomarkers , 2009, PloS one.

[20]  J. Lamba.  Genetic factors influencing cytarabine therapy. , 2009, Pharmacogenomics.

[21]  H. Iwasaki,et al.  Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells. , 2009, Biochemical pharmacology.

[22]  Christian Gieger,et al.  Meta-Analysis of 28,141 Individuals Identifies Common Variants within Five New Loci That Influence Uric Acid Concentrations , 2009, PLoS genetics.

[23]  K. Owzar,et al.  Auto-SCT for AML in second remission: CALGB Study 9620 , 2009, Bone Marrow Transplantation.

[24]  S. Mi,et al.  Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. , 2009, Blood.

[25]  A. P. Shaik,et al.  Meta-analysis study of glutathione-S-transferases (GSTM1, GSTP1, and GSTT1) gene polymorphisms and risk of acute myeloid leukemia , 2009, Leukemia & lymphoma.

[26]  M. Stephens,et al.  High-Resolution Mapping of Expression-QTLs Yields Insight into Human Gene Regulation , 2008, PLoS genetics.

[27]  M. Caligiuri,et al.  Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Schlenk,et al.  Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia , 2008, Leukemia.

[29]  Jianxiang Wang,et al.  Glutathione S-transferases (GSTT1 and GSTM1) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia. , 2008, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

[30]  A. Risch,et al.  Polymorphisms in transporter and phase II metabolism genes as potential modifiers of the predisposition to and treatment outcome of de novo acute myeloid leukemia in Israeli ethnic groups. , 2008, Leukemia research.

[31]  I. Oh,et al.  Efficacy of Gemcitabine in Patients with Non–Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene , 2008, Clinical Cancer Research.

[32]  John D. Storey,et al.  Mapping the Genetic Architecture of Gene Expression in Human Liver , 2008, PLoS biology.

[33]  D. Koller,et al.  Population genomics of human gene expression , 2007, Nature Genetics.

[34]  M. Pastor-Anglada,et al.  Role of CNT3 in the transepithelial flux of nucleosides and nucleoside‐derived drugs , 2007, The Journal of physiology.

[35]  M. Eileen Dolan,et al.  A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity , 2007, Proceedings of the National Academy of Sciences.

[36]  J. Roh,et al.  An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. , 2007, The oncologist.

[37]  N. Kröger,et al.  Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome , 2006, Bone Marrow Transplantation.

[38]  Ghada I. Mossallam,et al.  Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. , 2006, Journal of the Egyptian National Cancer Institute.

[39]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[40]  C. Cass,et al.  Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. , 2005, Biochemical pharmacology.

[41]  A. Klein-Szanto,et al.  Analysis of the In Vivo Functions of Mrp3 , 2005, Molecular Pharmacology.

[42]  Jiong Hu,et al.  Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. , 2004, Pharmacogenetics.

[43]  D. Steinbach,et al.  The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype. , 2003, Blood.

[44]  D. Steinbach,et al.  Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  C. Ries,et al.  Autologous stem cell transplantation for advanced acute myeloid leukemia , 2002, Bone Marrow Transplantation.

[46]  J. Beijnen,et al.  Characterization of Drug Transport by the Human Multidrug Resistance Protein 3 (ABCC3)* , 2001, The Journal of Biological Chemistry.

[47]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[48]  B. Andersson,et al.  Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. , 2013, Pharmacogenomics.

[49]  Brunangelo Falini,et al.  Mutational landscape of AML with normal cytogenetics: biological and clinical implications. , 2013, Blood reviews.

[50]  Iksoo Huh,et al.  Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. , 2013, European journal of cancer.

[51]  Verena I Gaidzik,et al.  TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R. Altman,et al.  Etoposide pathway. , 2009, Pharmacogenetics and genomics.

[53]  Jianxiang Wang,et al.  Glutathione S-transferases ( GSTT 1 and GSTM 1 ) genes polymorphisms and the treatment response and prognosis in Chinese patients with de novo acute myeloid leukemia , 2008 .

[54]  J. Roh,et al.  An Association Between RRM 1 Haplotype and Gemcitabine-Induced Neutropenia in Breast Cancer Patients , 2007 .

[55]  E. Burchard,et al.  Functional analysis of genetic variants in the human concentrative nucleoside transporter 3 (CNT3; SLC28A3) , 2005, The Pharmacogenomics Journal.

[56]  H. Rugo,et al.  Autologous stem cell transplantation for acute myeloid leukemia in first remission. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.